Drug Trial Radar · NCT06577259
Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Sep 3, 2024
Primary completion
Feb 19, 2025
Study completion Feb 19, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the relative bioavailability of BMS-986435 tablet formulations in healthy adult male and female participants.
Conditions
- Healthy Participants
Interventions
BMS-986435Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 105 days
- Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]Time frame: Up to 105 days
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]Time frame: Up to 105 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.